RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates interferon (IFN) signalling
Besides ONCY's pelareorep ability to directly lyse the cancer cell, pelareorep's ability to also activate the IFN-α signaling /pathways along with the down regulation of HIF-1α expression that results in "cross-talk" which remodels the hypoxic TME, pelareorep's down-regulation of HIFs can be viewed as an important step in the elimination of a tumor cancer cell. Because of pelareorep's down-regulation of HIF in the cancer cell, pelareorep would appear to also able to influence the down-regulation of CD47, CD73 and PD-L1 protein expression by a breast cancer cell, as an example, thus facilitating the effects of CD47, CD73 and PD-(L)1 inhibitors in the TME and on the innate and adaptive immune systems. CD47, CD73 and PD-L1 are genes involved in the evasion of cancer cells from innate and adaptive immunity. Facilitating the down-regulation of these genes in patients is thought to prevent the loss of T-cells within the TME.
Consequently, ONCY's pelareorep appears to be of signficant importance to Big Pharma companies, such as Pfizer, Roche, AstraZeneca (Medimmune), BMS, Novartis, Abbvie, and Gilead, as several examples of Big Pharma companies currently involved in the development of the above inhibitors.